Zhejiang Shengda Bio-Pharm Balance Sheet Health
Financial Health criteria checks 5/6
Zhejiang Shengda Bio-Pharm has a total shareholder equity of CN¥1.3B and total debt of CN¥240.0M, which brings its debt-to-equity ratio to 18.8%. Its total assets and total liabilities are CN¥1.7B and CN¥465.5M respectively.
Key information
18.8%
Debt to equity ratio
CN¥240.03m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥245.78m |
| Equity | CN¥1.27b |
| Total liabilities | CN¥465.54m |
| Total assets | CN¥1.74b |
Recent financial health updates
No updates
Recent updates
Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%
Oct 28
What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You
Aug 08Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive
Jun 12Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues
Apr 25Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Mar 08Financial Position Analysis
Short Term Liabilities: 603079's short term assets (CN¥666.9M) exceed its short term liabilities (CN¥239.9M).
Long Term Liabilities: 603079's short term assets (CN¥666.9M) exceed its long term liabilities (CN¥225.6M).
Debt to Equity History and Analysis
Debt Level: 603079 has more cash than its total debt.
Reducing Debt: 603079's debt to equity ratio has reduced from 34.6% to 18.8% over the past 5 years.
Debt Coverage: 603079's debt is well covered by operating cash flow (54.3%).
Interest Coverage: Insufficient data to determine if 603079's interest payments on its debt are well covered by EBIT.